Peptides > Tesamorelin (10 Vial Kit)

Tesamorelin (10 Vial Kit)

Tesamorelin is a synthetic analogue of growth-hormone-releasing hormone (GHRH) that is used clinically for the treatment of HIV-associated lipodystrophy (abnormal fat distribution in individuals with HIV). It is also being researched for its potential to improve peripheral nerve health and slow the progression of mild cognitive impairment while reducing fat mass.


This PRODUCT IS INTENDED AS A RESEARCH CHEMICAL ONLY. This designation allows the use of research chemicals strictly for in vitro testing and laboratory experimentation only. All product information available on this website is for educational purposes only. Bodily introduction of any kind into humans or animals is strictly forbidden by law. This product should only be handled by licensed, qualified professionals. This product is not a drug, food, or cosmetic and may not be misbranded, misused or mislabled as a drug, food or cosmetic.


1. What Is Tesamorelin?


2. Tesamorelin Structure


3. Tesamorelin Research

What Is Tesamorelin?

Tesamorelin, an analogue of growth hormone releasing hormone (GHRH), consists of regular GHRH with the addition of a trans-3-hexanoic acid group. Developed by Theratechnologies in Canada, it received FDA approval in 2010 for the management of HIV-associated lipodystrophy. Additionally, research has explored its potential in promoting the regeneration of peripheral nerves and as a prospective treatment for mild cognitive impairment (MCI), which is a precursor to dementia.

Tesamorelin Structure

Sequence (Single Letter): Unk-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu
Molecular Formula: C223H370N72O69S
Molecular Weight: 5195.908 g/mol
PubChem CID: 44147413
CAS Number: 901758-09-6

Tesamorelin Research

Tesamorelin: An Analogue of GHRH

Tesamorelin is an analogue of growth hormone-releasing hormone (GHRH), and it shares similar effects with GHRH and other GHRH analogues like sermorelin, GRF (1-29), and CJC-1295. The addition of trans-3-hexanoic acid to tesamorelin enhances its stability in human plasma, leading to an extended half-life. Despite this increase in half-life, tesamorelin, like CJC-1295, retains the physiological action of GHRH, resulting in fewer side effects compared to molecules that disrupt normal pulsatile growth hormone (GH) release.

Tesamorelin and its Role in Treating Lipodystrophy

Tesamorelin’s primary use is in the treatment of HIV-associated lipodystrophy, a condition that arises as a consequence of HIV infection and as a side effect of antiretroviral therapy. Lipodystrophy leads to excessive fat accumulation in various body areas, particularly the abdomen. The exact physiological mechanism behind this condition is not fully understood, but it is believed that commonly used protease inhibitors contribute significantly to its development.

Before tesamorelin, patients with lipodystrophy had limited treatment options, including diet, exercise, and a few ineffective medications. Surgical interventions were considered a last resort, often with limited success and potential complications. In 2010, the FDA approved tesamorelin specifically for the treatment of HIV-associated lipodystrophy. This drug has been found to reduce adiposity by nearly 20% in affected individuals. Research indicates that tesamorelin is approximately four times more effective in reducing adiposity than all other available therapies combined.

Tesamorelin’s Investigation in Cardiac Disease

People with HIV are at an increased risk of developing cardiovascular disease (CVD), partly due to abnormal fat deposition and the effects of antiretroviral drugs. Preventing CVD in HIV-positive individuals is considered a crucial medical intervention for long-term well-being, alongside highly active antiretroviral therapy (HAART).

Studies have shown that tesamorelin, in addition to reducing lipodystrophy, also lowers triglyceride levels, total cholesterol levels, and non-HDL-C levels in HIV-positive patients. A 15% reduction in visceral adipose tissue achieved through tesamorelin treatment correlates with a 50 mg decrease in triglyceride levels.

Tesamorelin’s Role in Reducing Inflammation and Cardiovascular Risk

Ectopic fat deposition, as observed in conditions like lipodystrophy, is associated with inflammation, which is a recognized risk factor for cardiovascular disease (CVD). Various types of fat, including visceral adipose tissue, liver fat, and epicardial fat, have independent associations with increased CVD risk. Tesamorelin, by reducing ectopic fat deposition, directly mitigates inflammation and lowers an individual’s risk of CVD.

Growth Hormone Deficiency and HIV

Recent evidence indicates that highly active antiretroviral therapy (HAART) is linked to several endocrine and metabolic issues, including growth hormone (GH) deficiency. HIV infection can alter the pituitary gland, leading to GH deficiency in approximately one-third of HAART-treated HIV patients. This may partly explain the prevalence of lipodystrophy in individuals with HIV and underscores why tesamorelin is such an effective treatment. Tesamorelin offers a safer and more effective means of increasing GH levels compared to administering exogenous GH, especially in HIV-positive individuals.

Tesamorelin’s Potential for Peripheral Nerve Damage

Peripheral nerve damage can result from various causes, including injury, diabetes, or surgical procedures. It often leads to severe motor and sensory impairments in the affected area, with limited options for correction due to the challenges associated with regenerating nerve cells. Emerging research suggests that therapies involving the manipulation of growth hormone may improve peripheral nerve injury and enhance both the rate and extent of healing. Among the candidates for such intervention, tesamorelin stands out, notably due to its existing FDA approval.

Tesamorelin’s Investigation in Dementia

There is accumulating evidence suggesting that GHRH analogues, including tesamorelin, exhibit effectiveness in enhancing cognitive function among patients in the early stages of dementia. A substantial, randomized, double-blind, placebo-controlled study conducted at the University of Washington School of Medicine, spanning twenty weeks, indicates that tesamorelin and other GHRH analogues may impact dementia by increasing gamma-aminobutyric acid (GABA) levels in the brain while reducing myo-inositol (MI) levels. These findings open up potential avenues for tesamorelin’s utilization in dementia treatment and also point to new areas for scientific exploration in the quest for dementia prevention and cures.


Tesamorelin Research

Because it is FDA approved for use in humans, tesamorelin is an attractive peptide for ongoing clinical research. It is currently under review for its ability to reduce cardiovascular disease in HIV, improve healing of peripheral nerves following injury, and slow the progression of dementia. Clinical trials are already underway in several different areas.

Tesamorelin exhibits minimal side effects, low oral and excellent subcutaneous bioavailability in mice. Per kg dosage in mice does not scale to humans. Tesamorelin for sale at Peptide Sciences is limited to educational and scientific research only, not for human consumption. Only buy Tesamorelin if you are a licensed researcher.

Article Author

The above literature was researched, edited and organized by Dr. Logan, M.D. Dr. Logan holds a doctorate degree from Case Western Reserve University School of Medicine and a B.S. in molecular biology.


The product information featured on this website pertains exclusively to in-vitro studies. In-vitro studies, also known as ‘in glass’ studies, are conducted outside of living organisms. It’s important to emphasize that these products do not constitute medicines or drugs and have not received FDA approval for the prevention, treatment, or cure of any medical conditions, ailments, or diseases. It is crucial to note that the introduction of these products into the bodies of humans or animals is strictly prohibited by law.